These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 17073688)

  • 21. Anti-immunoglobulin E therapy for asthma.
    Owen CE
    Pulm Pharmacol Ther; 2002; 15(5):417-24. PubMed ID: 12406663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etiopathogenesis and management of perennial allergic rhinitis: a state-of-the-art review.
    Bush RK
    Treat Respir Med; 2004; 3(1):45-57. PubMed ID: 15174893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapy of allergic bronchial asthma with omalizumab - an anti-IgE monoclonal antibody.
    D'Amato G
    Expert Opin Biol Ther; 2003 Apr; 3(2):371-6. PubMed ID: 12662149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma.
    Massanari M; Kianifard F; Zeldin RK; Geba GP
    Allergy Asthma Proc; 2009; 30(5):534-9. PubMed ID: 19467177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases.
    D'Amato G
    Eur J Pharmacol; 2006 Mar; 533(1-3):302-7. PubMed ID: 16464445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-IgE monoclonal antibody for the treatment of the asthma and other manifestations related to allergic diseases.
    Sarinho E; Cruz AA
    J Pediatr (Rio J); 2006 Nov; 82(5 Suppl):S127-32. PubMed ID: 17136288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-IgE for chronic asthma in adults and children.
    Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH
    Cochrane Database Syst Rev; 2004; (3):CD003559. PubMed ID: 15266491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.
    Kulus M; Hébert J; Garcia E; Fowler Taylor A; Fernandez Vidaurre C; Blogg M
    Curr Med Res Opin; 2010 Jun; 26(6):1285-93. PubMed ID: 20377320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-IgE monoclonal antibody, omalizumab: a new treatment for allergic asthma.
    Chung KF
    Expert Opin Pharmacother; 2004 Feb; 5(2):439-46. PubMed ID: 14996639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Omalizumab : other indications and unanswered questions.
    Mankad VS; Burks AW
    Clin Rev Allergy Immunol; 2005 Aug; 29(1):17-30. PubMed ID: 16222081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omalizumab: efficacy in allergic disease.
    Spector S
    Panminerva Med; 2004 Jun; 46(2):141-8. PubMed ID: 15507883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-IgE for chronic asthma.
    Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH
    Cochrane Database Syst Rev; 2003; (3):CD003559. PubMed ID: 12917972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of allergic rhinitis and other immunoglobulin E-mediated diseases with anti-immunoglobulin E antibody.
    Berger WE
    Allergy Asthma Proc; 2006; 27(2 Suppl 1):S29-32. PubMed ID: 16722329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab). An update.
    D'Amato G; Perticone M; Bucchioni E; Salzillo A; D'Amato M; Liccardi G
    Eur Ann Allergy Clin Immunol; 2010 Aug; 42(4):135-40. PubMed ID: 21114196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications].
    Kupryś-Lipińska I; Kuna P
    Pneumonol Alergol Pol; 2009; 77(1):43-51. PubMed ID: 19308909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of action of anti-immunoglobulin E therapy.
    Soresi S; Togias A
    Allergy Asthma Proc; 2006; 27(2 Suppl 1):S15-23. PubMed ID: 16722327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Omalizumab in asthma: an update on recent developments.
    Humbert M; Busse W; Hanania NA; Lowe PJ; Canvin J; Erpenbeck VJ; Holgate S
    J Allergy Clin Immunol Pract; 2014; 2(5):525-36.e1. PubMed ID: 25213045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden.
    Dewilde S; Turk F; Tambour M; Sandström T
    Curr Med Res Opin; 2006 Sep; 22(9):1765-76. PubMed ID: 16968580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody.
    Scheinfeld N
    Dermatol Online J; 2005 Mar; 11(1):2. PubMed ID: 15748543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.